Vistide cidofovir antiviral nucleotide analog of cystosine data

A Phase II/III trial in 48 AIDS patients with CMV peripheral retinitis found that Vistide delayed disease progression in previously untreated patients.

As reported in the Annals of Internal Medicine, patients were given immediate or deferred treatment with the agent. Progression was documented by photographing the retina, and patients in the deferred treatment group received the drug when progression

Read the full 599 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers